Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM): Pharmacokinetics And Dose Finding
Desaga, E.; Waetzig, G.H.; Liu, S.; Tran, F.; Laudes, M.; Schreiber, S.; Heyckendorf, J. · Aktuelle Ernährungsmedizin · 2025 · Heft 2 · S. 1 bis 1
Bibliografische Angaben
Zusammenfassung
Introduction: CICR-NAM is currently clinically evaluated for the treatment of disorders associated with dysregulated tryptophan metabolism. A recent placebo-controlled trial (COVit-2) demonstrated that supplementation with nicotinamide (NAM) including CICR-NAM improves gut microbial metabolic potential regarding tryptophan metabolism and accelerates recovery in COVID-19 patients. [(1)] Thus, CICR-NAM is a promising candidate to modulate inflammation-related disorders. Objectives: This study investigates the pharmacokinetics (PK) of CICR-NAM under inflammation-associated tryptophan depletion in hospitalized patie…